Eli Lilly and Co

Viking Therapeutics and Summit Therapeutics stocks doubled in 2024. Analysts predict Viking could reach $125, a 166% gain, and Summit could climb 68% to $30. Viking's VK2735, a weight loss drug, shows promising clinical trial results, while Summit's ivonescimab, a cancer therapy, outperforms Keytruda in trials.

Investment opportunities in weight-loss medicines include Zealand Pharma with its unique weight-loss drug survodutide in phase 3 trials and Eli Lilly, maker of potent weight-loss drug Zepbound, which is a blockbuster with significant future potential.

Duloxetine, sold under the brand name Cymbalta, was recalled due to the presence of a potentially cancer-causing nitrosamine, N-nitrosoduloxetine. Over 233,000 bottles were recalled by Rising Pharmaceuticals, with the FDA classifying it as a class II risk, indicating temporary or reversible health consequences. Duloxetine, an SNRI, is used to treat depression, pain, and anxiety by increasing neurotransmitters in the brain.

Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial for weight loss, with Zepbound users achieving 20.2% weight loss vs. 13.7% with Wegovy. Tirzepatide, in Zepbound, targets two gut hormones, enhancing its effectiveness over semaglutide in Wegovy. Full study results are pending publication.

The Indian pharmaceutical retail market rebounded in November with double-digit growth, driven by increased demand for dermatological, cardiac, and respiratory medications. Foracort, an asthma drug, topped sales at ₹82 crore. Urology, dermatology, cardiology, and pain relief therapies saw significant growth. Sun Pharma leads with an 8% market share. Analysts predict high-single-digit growth through 2025, driven by price increases and new product launches.

Cheryl Miller's Alzheimer's journey includes trials of drugs like Eli Lilly's Kisunla and Athira Pharma's medication, with mixed results. Despite setbacks, her husband John remains hopeful, seeking insurance coverage for Kisunla and exploring new trials. The article highlights the emotional toll on caregivers and the ongoing search for effective treatments.

India's organized pharma retail market grew 11% in November, led by derma, cardiac, and respiratory drugs. Foracort topped sales at Rs 82 crore, followed by Augmentin and Glycomet GP. Urology, derma, cardiac, and pain-relief segments grew 18%, 16%, 13%, and 13% respectively. Sun Pharma led with an 8% market share, while domestic companies slightly outpaced MNCs. The market is expected to grow in high single digits by 2025, driven by price increases and new launches, including GLP-1 drugs.

The article discusses the importance of summarizing content effectively, focusing on clarity and brevity while retaining the original expressions.

Eli Lilly announced EMA's CHMP positive opinion for Omvoh (mirikizumab) for treating adults with moderately to severely active Crohn's disease. Omvoh, an IL-23p19 antagonist, aims to provide comprehensive disease control, including symptom relief and intestinal inflammation control. The positive opinion moves Omvoh closer to European regulatory approval, pending European Commission's decision within one to two months.

Editas Medicine lays off 65% of staff, shelving its sickle cell disease treatment Reni-Cel; Ionis Pharmaceuticals shifts to in-house drug commercialization; GLP-1 drugs spark debate in Trump's circle; investors sue Bristol Myers Squibb over Padlock Therapeutics milestone payments.